BALTIMORE--(BUSINESS WIRE)--WellDoc® announces the appointments of Dr. David Levy, Terry Lierman, Donald Almeida and Michael Greenebaum to its Board of Directors. In addition, the company has formed a new strategic advisory board that includes Dr. Michael Stocker, Rt Hon Alan Milburn, H. Tom Watkins, and Christopher T. Rogers. These global healthcare and technology executives add experience and guidance to the company during the launch and commercialization of BlueStar™, the first FDA cleared, reimbursable, mobile prescription therapy for type 2 diabetes.
“We are proud to welcome David, Terry, Don and Michael to our Board of Directors and Mike, Alan, Tom, and Chris as advisors,” stated Ryan Sysko, Founder and CEO of WellDoc. “Each addition brings unique local and global experiences from private industry, healthcare, technology, and policymaking backgrounds. Their collective knowledge will be invaluable to the growth of our company.”
“WellDoc sits at the center of the convergence of healthcare, big data, and the mobile Internet. Their products couldn’t have come at a better time as they empower doctors, patients, and payers to succeed in the era of healthcare reform,” explained Dr. David Levy former Global Healthcare Leader for PwC. “I’m humbled to serve the company alongside individuals who literally crafted today’s ground breaking healthcare policies both in the U.S. and in Europe and who have built multi-billion dollar successful businesses,” he added.
Collectively these executives are investing in the future of patient centered care to improve health outcomes and lower costs. Their appointment marks an important achievement for WellDoc as it continues its leadership position in engaging patients and enhancing outcomes through the use of clinical algorithms, behavioral science, and digital health technology.
Additions to the Board of Directors
David Levy, M.D. has been a champion of patient-centric medicine and the use of technology to disrupt and improve healthcare delivery. As the Global Healthcare Leader, he forged global alliances and developed new business and delivery models for PwC's clients. Under Dr. Levy’s leadership, PwC developed a particular focus on mobile health technology and its vast potential in emerging markets.
Dr. Levy began his career as a primary care physician and epidemiologist, successfully founding a large primary care practice in suburban New York City. As a quality consultant for large health insurers, he saw the opportunity to rethink how complex patients were treated in the US healthcare system and created Franklin Health Group, one of the nation’s first disease management companies, and led it through a successful acquisition to a global point-of-care diagnostics company.
Terry Lierman is a renowned advocate for improving healthcare delivery and supporting medical research. Over the last four decades, his public service has significantly shaped public policy and his entrepreneurial talent has provided for success across the private healthcare and technology sectors.
Mr. Lierman began his career in the public sector at the National Institutes of Health (NIH) and today is frequently noted as one of the most influential persons in healthcare policy. During his years of public service he held U.S. Senate Staff leadership positions including serving as the youngest Staff Director of the Labor Health and Human Services (HHS) Appropriations Committee, leading the Maryland Democratic Party through the successful elections of Governor Martin O’Malley and Senator Ben Cardin, and serving as the Chief of Staff to the House of Representatives Majority Leader and Democratic Whip Congressman Steny H. Hoyer.
In the private sector, Mr. Lierman founded non-profit organizations that advanced healthcare advocacy including the Children’s Research Institute at Children’s Hospital National Medical Center, National Coalition for Cancer Research, the National Organization on Fetal Alcohol Syndrome (NOFAS), and the Pancreatic Cancer Action Network (PANCAN).
Donald V. Almeida recently retired as Vice Chairman of PwC where he led PwC's Global Markets and Industries program, including the Healthcare, Pharmaceutical, Life Sciences and Government practices. Mr. Almeida also served on the US and Global Boards of PwC. He has more than 30 years of experience in PwC’s Assurance practice principally with large multinational public companies. He brings to WellDoc extensive experience working with early stage and multinational companies.
He is a member of the American Institute of Certified Public Accountants, the Fordham Business Schools Advisory Board and the Fordham President’s Council and will soon be serving on a number of Boards.
Michael I. Greenebaum is president of Greenebaum Enterprises, Inc., a regional real estate development company. Mr. Greenebaum has more than 25 years of experience in all facets of the commercial and residential development industry. He is currently developing Maple Lawn, a 600 acre mixed-use community in Howard County Maryland. Mr. Greenebaum serves on the board of the Greenebaum Family Foundation, which continues the philanthropy of his family by focusing on the improvement of the human condition through education and medicine. He also is a board member for both the University of Maryland Marlene and Stewart Greenebaum Cancer Center and the University of Maryland School of Medicine. He is co-founder of the Maryland Half Marathon and serves on the McDonogh School Board of Trustees, as well as several other civic and community organizations.
Strategic Advisory Board Members
Michael Stocker, M.D. serves as the Chairman of the Board of the New York City Health and Hospitals Corporation (HHC), the largest municipal hospital and healthcare system in the country, serving 1.3 million New Yorkers annually. Prior to this role, he served as executive vice president of WellPoint, chief executive officer of Empire Blue Cross and Blue Shield, president of Cigna Health Plans, and general manager of U.S. Healthcare. He has also held many board positions including being a Board Member at FAIR Health and Coventry Health Care, which was recently acquired by Aetna. Dr. Stocker also frequently volunteers his expertise in healthcare administration across public and private organizations. Presently he is a board member of the Arthur Ashe Institute for Urban Health as well as the United Hospital Fund and he previously served as a member of the New Jersey Governor's Health Care Cost Reduction Advisory Committee and the National Committee for Quality Assurance (NCQA).
Earlier in his career, Dr. Stocker was a practicing physician at Cook County Hospital in Chicago and a medical director at Anchor HMO at Rush Presbyterian St. Luke's Medical Center. Dr. Stocker was educated at the University of Notre Dame and received his M.D. from the Medical College of Wisconsin. He received his postgraduate training at the Mayo Clinic and the University of California and is board certified in Internal Medicine and Family Practice. Dr. Stocker also holds a Master's degree in Public Health from the University of Michigan and he served his country in the United States Army.
Rt Hon Alan Milburn served in the United Kingdom government as a Member of Parliament and a Cabinet minister under Prime Minister Blair where he held the roles of Secretary of State for Health, Chief Secretary to the Treasury, and Chancellor of the Duchy of Lancaster. While overseeing the National Health Service (NHS) he worked to reduce waiting times, modernize healthcare delivery, and improve the performance of the health system. Mr. Milburn has subsequently been appointed by Prime Minister Cameron as Chair of the Social Mobility and Child Poverty Commission.
Today, Mr. Alan Milburn serves as the Chairman of the European Advisory Board of Bridgepoint Advisers Limited. He is also Chair of the Global Advisors for Mars Incorporated and is Chair of PwC's UK Health Industries Oversight Board. He is chairman of iWantGreatCare Ltd and serves as Non-Executive Director of Diaverum AB.
H. Thomas Watkins served as the President and Chief Executive Officer of Human Genome Sciences, Inc. and as a member of its Board of Directors from 2005 until August 2012, when Human Genome Sciences, Inc. was acquired by GlaxoSmithKline. Prior to his tenure at Human Genome Sciences, Inc., Mr. Watkins served as President of TAP Pharmaceutical Products, Inc. Mr. Watkins previously held a series of executive positions over the course of nearly twenty years with Abbott Laboratories. Mr. Watkins also serves on the Board of Directors of the Biotechnology Industry Organization (BIO), and has served as Chair of the BIO Board of Directors. Previously he was appointed by Governor O’Malley to Chair the Life Sciences Advisory Board for the state of Maryland. He holds a B.B.A. from the College of William and Mary and an M.B.A from the University of Chicago Graduate School of Business.
Christopher T. Rogers, J.D. was the co-founder of Nextel Communications (sold to Sprint for $35 billion) and several of its predecessor companies. Mr. Rogers brings 30 years of mobile industry experience as a founder, advisor and operator. Most recently, Rogers served as Senior Vice President, Corporate Development and Spectrum, of Sprint where he evaluated and executed strategic initiatives, including mergers, acquisitions, divestitures, equity investments and joint ventures within the mobile communication and e-commerce sectors. He also was responsible for management and oversight of wireless spectrum licenses and Sprint’s investment portfolio of emerging technology start-ups. Prior to the 2005 Sprint Nextel merger, Rogers was Co-Founder and Senior Vice President of Nextel Communications, Inc. Before Nextel Communications, Rogers was co-Founder of FleetCall Communications, the predecessor to Nextel Communications, and Founder and Chairman of Dispatch Communications, which was sold to Fleet Call/Nextel in 1993. Rogers served as a director on multiple public and private company boards and as a director for several Washington, D.C.-based philanthropic organizations.
He received his JD from the Columbus School of Law at Catholic University and his bachelor's degree from Tufts University.
###
About WellDoc: Engaging Patients, Enhancing Outcomes™
WellDoc, a healthcare behavioral science and technology company that develops solutions aimed at engaging patients and enhancing health outcomes, is focused on simplifying the way chronic diseases are managed through a collaborative, life-changing approach that breaks down the barriers of engagement and adherence by providing patients and their healthcare providers with real-time, actionable information. WellDoc has developed an industry-leading, technology-based solution designed to help people with chronic diseases better manage their conditions. Forbes selected WellDoc as one of “America's Most Promising Companies” based on its potential for future growth.
For more information, visit www.welldoc.com and www.BlueStarDiabetes.com
